Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Long-term overall survival of AYA patients with ALL who complete therapy on DFCI Consortium trials

Marlise Luskin • 11 Dec 2022
ASH 2022
Acute Lymphoblastic Leukemia Leukemia

Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, briefly discusses treatment outcomes in adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) treated with Dana-Farber Cancer Institute (DFCI) ALL Consortium protocols. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Abbvie: Research Funding; Pfizer: Honoraria; Novartis: Research Funding.

More from Marlise Luskin

MRD assessment and biologic risk stratification shape personalized care in ALL
3:25
MRD assessment and biologic risk stratification shape personalized care in ALL
Marlise Luskin • 5 Jun 2026
Results of a Phase II study of venetoclax plus mini-hyper-CVD in older adults with Ph-negative ALL
6:32
Results of a Phase II study of venetoclax plus mini-hyper-CVD in older adults with Ph-negative ALL
Marlise Luskin • 5 Jun 2026
Evolving treatment strategies and unmet needs in acute lymphoblastic leukemia
3:38
Evolving treatment strategies and unmet needs in acute lymphoblastic leukemia
Marlise Luskin • 5 Jun 2026
Blinatumomab, inotuzumab & venetoclax in older patients with ALL: practical considerations
4:48
Blinatumomab, inotuzumab & venetoclax in older patients with ALL: practical considerations
Marlise Luskin • 27 Feb 2026

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals